Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1929457
Max Phase: Preclinical
Molecular Formula: C15H16N6O
Molecular Weight: 296.33
Molecule Type: Small molecule
Associated Items:
ID: ALA1929457
Max Phase: Preclinical
Molecular Formula: C15H16N6O
Molecular Weight: 296.33
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1ncc(Cn2cc(COc3ccccc3)nn2)c(N)n1
Standard InChI: InChI=1S/C15H16N6O/c1-11-17-7-12(15(16)18-11)8-21-9-13(19-20-21)10-22-14-5-3-2-4-6-14/h2-7,9H,8,10H2,1H3,(H2,16,17,18)
Standard InChI Key: LDHXDHASNDWZPB-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 296.33 | Molecular Weight (Monoisotopic): 296.1386 | AlogP: 1.59 | #Rotatable Bonds: 5 |
Polar Surface Area: 91.74 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 5.97 | CX LogP: 1.65 | CX LogD: 1.64 |
Aromatic Rings: 3 | Heavy Atoms: 22 | QED Weighted: 0.77 | Np Likeness Score: -1.68 |
1. Ren Y, He J, Feng L, Liao X, Jin J, Li Y, Cao Y, Wan J, He H.. (2011) Structure-based rational design of novel hit compounds for pyruvate dehydrogenase multienzyme complex E1 components from Escherichia coli., 19 (24): [PMID:22078411] [10.1016/j.bmc.2011.10.035] |
2. He J, Feng L, Li J, Tao R, Wang F, Liao X, Sun Q, Long Q, Ren Y, Wan J, He H.. (2012) Design, synthesis and biological evaluation of novel 2-methylpyrimidine-4-ylamine derivatives as inhibitors of Escherichia coli pyruvate dehydrogenase complex E1., 20 (5): [PMID:22305934] [10.1016/j.bmc.2012.01.019] |
3. He H, Wang W, Zhou Y, Xia Q, Ren Y, Feng J, Peng H, He H, Feng L.. (2016) Rational design, synthesis and biological evaluation of 1,3,4-oxadiazole pyrimidine derivatives as novel pyruvate dehydrogenase complex E1 inhibitors., 24 (8): [PMID:26972920] [10.1016/j.bmc.2016.03.011] |
4. Feng J, He H, Zhou Y, Guo X, Liu H, Cai M, Wang F, Feng L, He H.. (2019) Design, synthesis and biological evaluation of novel inhibitors against cyanobacterial pyruvate dehydrogenase multienzyme complex E1., 27 (12): [PMID:30692021] [10.1016/j.bmc.2019.01.021] |
Source(1):